sur Innoscripta AG (isin : DE000A40QVM8)
Innoscripta SE Enters US Market Addressing New IRS R&D Documentation Needs
innoscripta SE has marked a successful entry into the US market, securing key customers shortly after its launch. The company, based in Tutzing, has attracted an international technology group from New York and a Minnesota-based clinical trial software provider. This expansion aligns with innoscripta's strategy to grow its international presence.
The urgency for structured R&D documentation is heightened due to new IRS requirements under Form 6765, Section G. This necessitates detailed reporting of research expenditures. innoscripta's Clusterix software offers a solution, providing transparent and detailed project documentation.
The US remains a leading R&D hub, with companies investing over EUR 570 billion in 2025. innoscripta aims to significantly increase its international revenue share by leveraging this vast market potential.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Innoscripta AG